MARS expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | <1E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.65680025254744E-10 |
Normal-vs-Stage2 |
2.12229999999591E-05 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.832380E-04 |
Stage1-vs-Stage2 |
6.611200E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
2.120000E-02 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
5.077500E-02 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
1.62492241884138E-12 |
Normal-vs-AfricanAmerican |
2.007800E-01 |
Normal-vs-Asian |
1.707960E-02 |
Caucasian-vs-AfricanAmerican |
5.397800E-01 |
Caucasian-vs-Asian |
1.039610E-01 |
AfricanAmerican-vs-Asian |
6.163000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
5.99580000093525E-08 |
Normal-vs-Female |
6.77236045021345E-12 |
Male-vs-Female |
2.976000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
4.038400E-04 |
Normal-vs-Extreme_Weight |
9.78639391746583E-12 |
Normal-vs-Obese |
4.979500E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
1.306240E-01 |
Normal_Weight-vs-Obese |
4.833000E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
6.863200E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.426600E-01 |
Normal-vs-Age(41-60Yrs) |
1.81160000001235E-06 |
Normal-vs-Age(61-80Yrs) |
1.21890053605966E-10 |
Normal-vs-Age(81-100Yrs) |
1.160580E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.013800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.117000E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.335600E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.872200E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.874000E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.011600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
5.219200E-01 |
Normal-vs-Grade 3 |
9.827700E-02 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
5.318100E-02 |
Grade 2-vs-Grade 4 |
5.219200E-01 |
Grade 3-vs-Grade 4 |
9.827700E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.50990331349021E-14 |
Normal-vs-N1 |
4.403200E-04 |
N0-vs-N1 |
9.868200E-02 |
|
|